Introduction
Head and neck squamous cell carcinoma (HNSCC) is the sixth most frequent cancer worldwide (5 th in the United States) with a cancer associated five-year survival rate less than 50% (reviewed in (1-4) ). Risk factors include tobacco use, alcohol consumption, human papilloma virus exposure and genetic disorders such as Fanconi Anemia. Mutations in welldefined oncogene drivers such as KRAS and EGFR are generally rare in HNSCC relative to other solid tumors such as non-small cell lung cancer (2) . Yet, frequent over-expression of EGFR and EGFR ligands is seen in HNSCC tumors, with EGFR over-expression identified in up to 90% of tumors (3, 5) . Based on this rationale, EGFR-specific tyrosine kinase inhibitors (TKIs) and blocking antibodies such as cetuximab have been tested in HNSCC patients. Cetuximab yielded modest increases in patient survival when used in combination with standard chemo-and radiotherapies and has been an approved treatment for HNSCC since 2006 (reviewed in (2, 6) ).
The increasing understanding of tumor heterogeneity dictated by the different driver oncogenes dominant in distinct subsets of tumors has led to the concept of personalized therapy in NSCLC, breast cancer and colorectal cancer (7) (8) (9) . By contrast, personalized treatment approaches for HNSCC lag behind, due in part to limited information on the dominant oncogenes in this cancer. In this regard, the modest impact of EGFR inhibitors observed in HNSCC may, in fact, reflect an averaged response whereby a subset of highly EGFR-dependent tumors exist within a larger set of EGFR-independent tumors. As a precedent, the initial clinical evaluation of EGFR-specific TKIs in lung cancer patients noted a rather small benefit in survival relative to the larger responses when treatment was restricted to patients with lung tumors bearing mutated EGFR (8, 10 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
Author Manuscript Published OnlineFirst on June 14, 2011; DOI: 10.1158/1078-0432.CCR- cetuximab in HNSCC with EGFR protein expression (2) or EGFR gene copy number (11) have proven negative. Thus, it will be necessary to stratify HNSCC into therapy-responsive subsets by a means other than the simple EGFR expression or mutation.
We hypothesize that the insensitivity of the majority of HNSCC to EGFR inhibitors is mediated by dominant activity of alternative receptor tyrosine kinase (RTK) systems in distinct subsets of tumors. Among RTKs with reported activity in HNSCC, the literature highlights roles for cMet (12) , IGF-1R (13) and cooperative roles between PDGFR and VEGFR (14) . Although no functionality has been explored, co-expression of FGFs and FGFRs has also been observed in HNSCC tumors compared to normal epithelia and dysplastic lesions of the head and neck (15, 16) . We, and others, have demonstrated that FGF2 and FGFRs participate in autocrine signaling contributing to both intrinsic and acquired EGFR TKI resistance in non-small cell lung cancer cell lines (17) (18) (19) . In fact, a general role for FGFs and FGFRs is emerging in multiple cancers (Reviewed in (20) (21) (22) ) including prostate (23, 24) , thyroid (25, 26) , skin (27, 28) , lung (Reviewed in (29) ), urinary bladder (30, 31) , and head and neck (15, 32) cancers. Taken together, these studies show FGF and FGFR-mediated oncogenesis through gene amplification, somatic mutations, and increased expression of FGFs and/or FGFRs in human cancer. Thus, FGFs and FGFRs are likely to play roles in cancer equal to or greater in scope to that of EGFR.
The family of FGFs is encoded by 22 distinct genes that bind and activate a family of four receptor tyrosine kinases designated FGFR1 -FGFR4 (20) (21) (22) . The extracellular domain of cells. This establishes a paracrine mechanism of signaling between epithelia and mesenchyme that is critical to normal development and tissue homeostasis. Moreover, FGFs and FGFRs become involved in oncogenesis through acquisition of somatic mutations within the receptors that confer gain-of-function, over-expression of a specific FGFR or inappropriate expression of one or more FGFs to establish autocrine or paracrine signaling (20) (21) (22) . In regards to the latter, FGF genes are targets of murine mammary tumor virus equal in frequency to the WNT genes and mediate virus-dependent murine mammary tumorigenesis (33) .
In a recent study, we demonstrated an autocrine growth factor role for FGF2 or FGF9 and FGFR1 and FGFR2 in NSCLC, especially in cell lines of squamous and large cell histology (18) .
The demonstration of selective FGFR1 gene amplification in lung squamous cell carcinomas and lung cancer cell lines further supports the role of the FGFR signaling pathway in specific lung cancer histologies (34) . In the present study, we have explored the involvement of FGF and FGFR autocrine signaling in HNSCC, also of squamous histology. Our studies reveal frequent co-expression of FGF2 and FGFRs in HNSCC cell lines, thereby instituting an autocrine loop that, alone or in collaboration with EGFR, drives cell growth. FGF2 and FGFRs may define a distinct subset of HNSCC tumors that can be targeted with emerging FGFR-specific TKIs (22) . days and viable colonies were stained for 24 hrs with 200 μl of 1 mg/ml nitroblue tetrazolium.
Digital photographs of wells were used to quantify colonies using the MetaMorph program.
FGF2 ELISA. HNSCC cell lines were cultured in HITES medium for 24 hours.
Subsequently, the rinsed cell monolayers were lysed in 250 μl MAP Kinase Lysis buffer (MKLB; 0.5% Triton X-100, 50 mM β-glycerophosphate (pH 7.2), 0.1 mM Na 3 VO 4 , 2 mM MgCl 2 , 1 mM EGTA, 1mM DTT, 0.3 M NaCl, 2 μg/ml leupeptin and 4 μg/ml aprotinin) and supernatants from centrifuged lysates were assayed for FGF2 using a Quantikine-human FGF (Santa Cruz Biotechnology, Inc., Santa Cruz, CA) for 1 hour and developed with LumiPhos reagent (Pierce, Rockford, IL) according to the manufacturer's instructions. The filters were then stripped and re-probed for total ERK1 and ERK2 using a mixture of rabbit polyclonal anti-ERK1 (sc-93) and ERK2 (sc-154) (Santa Cruz Biotechnology, Inc., Santa Cruz, CA).
For immunoblot analysis of FGFR1, FGFR2, FGFR3, EGFR, and the NaK-ATPase α-subunit, MKLB extracts from HNSCC cells were submitted to SDS-PAGE using 7.5% acrylamide separating gels. Nitrocellulose filters were blocked in 3% non-fat dehydrated milk in TTBS for one hour at room temperature and incubated with antibodies to FGFR1 (sc-57132), FGF2 mRNA levels in primary human oral keratinocytes (HOK) and immortalized human keratinocytes (HaCaT) were markedly lower than expression levels in the HNSCC cell lines and human gingival fibroblasts (HGF1) (Fig. 3A) . Similarly, the level of FGFR1 protein expression in HOK and HaCaT cells was undetectable compared to the level measured in 584-A2 cells and the gingival fibroblasts (Fig. 3B) . By contrast, the relatively high levels of FGFR2 and FGFR3 in UMSCC8 cells (relative to the other 8 HNSCC cell lines) were similar to expression observed in HaCaT and HOK cells (Fig. 3B) . Thus, a simple interpretation of these data are that FGF2 and FGFR1 levels are increased in HNSCC cell lines, but FGFR2 and FGFR3 are retained at expression levels similar to non-transformed oral epithelia modeled by HaCaT and HOK cells. (19) reduced phospho-ERK levels similarly to RO4383596 (Supplementary Figure 1) , supporting the interpretation that FGFRs are driving signaling of the ERK pathway in these cell lines. The EGFR inhibitor, AG1478, inhibited ERK signaling in all three of these particular cell lines.
Based on this signaling endpoint, some cell lines (584-A2, CCL30 and Detroit 562) exhibit dependence solely on FGFR signaling, while others are completely dependent on EGFR signaling (UMSCC19, HN4, HN31). Finally, Ca9-22, UMSCC25 and UMSCC8 responded to both TKIs with inhibition of basal ERK phosphorylation. This indicates three response groups in HNSCC cell lines, two groups depending on either FGFR or EGFR signaling, respectively, and a third group that apparently engages both RTK pathways.
To determine if TKI-induced inhibition of ERK signaling correlated with effects on HNSCC cell growth, the effect of AG1478 or RO4383596 was tested on anchorage-independent or clonogenic growth. As predicted from the findings in Figure 4 , growth of CCL30, Detroit562, and 584-A2 was inhibited by RO4383596, but not AG1478 (Fig. 5A and B) . By contrast, growth of cell lines exhibiting dominant EGFR signaling (UMSCC19, HN4 and HN31) was reduced by AG1478, but not RO4383596 (Fig. 5C and D) . Finally, UMSCC8, UMSCC25 and Ca9-22 exhibited concentration-dependent reduction in growth in response to either TKI ( Fig. 5E and F 
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AG1478 or RO4383596 and a further inhibition was observed in response to combined treatment with these TKIs (Fig. 6A) . Growth of UMSCC8 and Ca9-22 cells was significantly reduced by AG1478 alone, but not by RO4383596 alone. However, treatment with combined AG1478 and RO4383596 induced significantly greater growth inhibition than AG1478 alone (Fig. 6A) .
Nearly identical results were obtained when the three HNSCC cell lines were treated with chemically-distinct EGFR and FGFR-specific TKIs, gefitinib and AZ12908010 (19) , respectively (Fig. 6B) . Moreover, the EGFR-specific TKIs can be replaced with cetuximab, an anti-EGFR antibody inhibitor with similar results (Fig. 6C) . These results indicate that a third distinct subset of HNSCC lines exist in which both FGFR and EGFR pathways are simultaneously engaged to drive maximal growth. These results are consistent with the functioning of coactivation networks whereby multiple distinct RTKs simultaneously engage in oncogenic signaling rather than single monolithic receptors (37) . mRNA and protein relative to the other cell lines (Fig. 2) . However, a FISH-based analysis of fgfr1 gene copy number in 584-A2 cells revealed no evidence for fgfr1 amplification (data not shown). Regarding a role for somatic gain-of-function mutations in specific FGFRs, a published report revealed frequent (62%) mutation of FGFR3 (G697C) in primary HNSCC derived from Japanese patients (42) . However, an independent screening of a French head and neck cancer patient population revealed no evidence for this FGFR3 mutation (43) . Also, the COSMIC database reveals no identified FGFR3 mutations in any of the 22 HNSCC cell lines that were sequenced. Thus, it is possible that FGFR3 mutations may be highly restricted to HNSCC derived from specific ethnic populations. As precedent, gain-of-function mutations in EGFR are significantly more frequent in patients of Asian ethnicities (44) .
As an alternative mechanism for the observed FGF2 and FGFR2/FGFR3 co-expression in HNSCC cell lines, we propose that FGFR2 and FGFR3 are expressed in normal epithelial cell precursors exemplified by HOK and HaCaT cells (see Fig. 2 ) and simply retained and co-opted Despite over-expression in ~90% of HNSCC tumors, EGFR inhibitors have not exerted a major therapeutic impact in this particular cancer (reviewed in (1-4) ). In fact, our previous study (35) and present experiments (see Fig. 5 ) indicate that only a subset of HNSCC cell lines exhibit a significant growth inhibitory response to EGFR-specific TKIs as single agents. Currently, the only EGFR targeted therapy approved for treatment of locally advanced HNSCC tumors is the 
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antibody-based therapeutic, cetuximab, which has shown modest benefit in patients when used in conjunction with chemotherapy or radiotherapy (2, 6) . Clearly, expression of EGFR protein is not an accurate indicator of EGFR dominance in primary HNSCC tumors or in HNSCC cell lines (see Fig. 2A, Supplementary Table 2 and (2, 11) ). Importantly, the efficacy of EGFR-specific TKIs for treatment of lung cancer was largely underestimated in early trials that failed to appreciate that activity was largely restricted to those lung adenocarcinomas bearing gain-offunction mutations in EGFR (8) . Thus, the relatively weak clinical effects of EGFR inhibitors in HNSCC is predicted from the absence of somatic gain-of-function mutations in EGFR in this cancer (48) and the failure of trials to selectively target the subset of HNSCC tumors in which EGFR is dominant.
Mutations in defined oncogene drivers such as Ras family members, PIK3CA and distinct RTKs are rare in HNSCC relative to non-small cell lung cancer where subsets of lung cancers bearing mutations in KRas, PIK3CA, EGFR, ERBB2, ALK and BRAF have emerged (48, 49) . Considering that targeted therapy strategies depend on matching inhibitors with tumors bearing their mutated oncogene targets, the deployment of targeted therapies in HNSCC is somewhat problematic. Importantly, this issue is not limited to HNSCC as at least 50% of nonsmall cell lung tumors presently lack defined mutations in oncogenic drivers (49) . In spite of this issue, we propose that RTKs may still serve as useful targets for therapeutics in HNSCC.
Beyond our findings showing roles for EGFR and FGFRs in HNSCC growth, published studies have indicated roles for additional RTKs including IGF-1R, Met, PDGFR and VEGFR (12) (13) (14) .
In fact, this study and others (48) , provide support for the concept of RTK coactivation networks (37) as the more accurate representation of oncogenic growth factor inputs in HNSCC. Our 
